{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"3.1","upperLimit":"12.4","value":"3.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"19"}],"units":"Participants"}],"title":"ACC"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.6","upperLimit":"9.2","value":"2.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"17"}],"units":"Participants"}],"title":"Non-ACC"}],"denoms":[{"counts":[{"groupId":"OG000","value":"36"}],"units":"Participants"}],"dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receive oral lapatinib once daily on days 1-28. Courses repeat every 28 days in the absence of unacceptable toxicity or disease progression.\n\nlapatinib ditosylate: Given orally\n\nlaboratory biomarker analysis: Correlative studies","id":"OG000","title":"Treatment (Lapatinib Ditosylate)"}],"paramType":"MEDIAN","populationDescription":"36 assessable participants, 19 with ACC and 17 with non-ACC.","reportingStatus":"POSTED","timeFrame":"From the date of study enrolment to disease progression, death or last contact, or last tumor assessment before the start of further anti-tumor therapy, assessed up to 5 years","title":"Progression-free Survival (PFS) According to RECIST","type":"SECONDARY","unitOfMeasure":"months"}